Hematopoietic stem cell transplantation in nonmalignant diseases

Journal of Rheumatology

Volumn 24, Issue SUPPL. 48, 1997, Pages 30-35

  Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aplastic anemia; Genetic hematological diseases; Graft rejection; Graft versus host disease; Marrow transplantation

Indexed keywords

BUSULFAN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; PROCARBAZINE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THALASSEMIA MAJOR; WHOLE BODY RADIATION; ACUTE DISEASE; ADOLESCENT; ADULT; BETA THALASSEMIA; CHILD; CHRONIC DISEASE; DISEASE FREE SURVIVAL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METHODOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROGNOSIS; REGISTER; REVIEW; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANEMIA, APLASTIC; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 0030920514     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Deeg HJ, Sale GE, Storb R, et al: Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate. Transplantation 1987;44:340-5.
2. Yu C, Storb R, Mathey B, et al: DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995;86:4376-81.
3. Storb R: Bone marrow transplantation for aplastic anemia. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation Boston: Blackwell Scientific, 1994:583-94.
4. Storb R, Etzioni R, Anasetti C, et al: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994;84:941-9.
5. Feig SA, Champlin R, Arenson E, et al: Improved survival following bone marrow transplantation for aplastic anemia. Br J Haematol 1983;54:509-17.
6. Smith BR, Guinan EC, Parkman R, et al: Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation 1985;39:671-3.
7. McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NKC: Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood 1987;70:1325-30.
8. Bacigalupo A, Hows J, Gluckman E, et al: Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party. Br J Haematol 1988;70:177-82.
9. Hows JM, Marsh JC, Yin JL, et al: Bone marrow transplantation for severe aplastic anemia using cyclosporin: Long-term follow-up. Bone Marrow Transplant 1989;4:11-6.
10. Champlin RE, Ho WG, Nimer SD, et al: Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy. Transplantation 1990;49:720-4.
11. Locasciulli A, van't Veer L, Bacigalupo A, et al: Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: A report from the EBMT SAA Working Party. Bone Marrow Transplant 1990;6:211-7.
12. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM: Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: Long-term follow-up. Blood 1991;78:2451-5.
13. Gluckman E, Horowitz MM, Champlin RE, et al: Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992;79:269-75.
14. Socie G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E: Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1997;78:277-9.
15. Deeg HJ, Socié G, Schoch G, et al: Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386-92.
16. Storb R, Doney KC, Thomas ED, et al: Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982;59:236-46.
17. Storb R, Prentice RL, Sullivan KM, et al: Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983;98:461-6.
18. Storb R, Weiden PL, Deeg HJ, et al: Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: Antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood 1979;54:477-84.
19. Deeg HJ, Aprile J, Storb R, et al: Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients. Blood 1988;71:1138-40.
20. Bean MA, Graham T, Appelbaum FR, et al: Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation 1994;51:423-6.
21. Storb R, Floersheim GL, Weiden PL, et al: Effect of prior blood transfusions on marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974;112:1508-16.
22. Storb R, Weiden PL, Sullivan KM, et al: Second marrow transplants in patients with aplastic anemia rejecting the first graft: Use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987;70:116-21.
23. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED: Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 1977;24:349-57.
24. Tutschka PJ, Santos GW: Bone marrow transplantation in the busulfan-treated rat. Transplantation 1975;20:101-6.
25. Thomas ED, Buckner CD, Sanders JE, et al: Marrow transplantation for thalassaemia. Lancet 1982;2:227-9.
26. Walters MC, Sullivan KM, O'Reilly RJ, et al: Bone marrow transplantation for thalassemia: The USA experience. Am J Pediatr Hematol Oncol 1994;16:11-7.
27. Lucarelli G, Galimberti M, Polchi P, et al: Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322:417-21.
28. Lucarelli G, Galimberti M, Polchi P, et al: Marrow transplantation in patients with advanced thalassemia. N Engl J Med 1987;316:1050-5.
29. Lucarelli G, Clift RA: Bone marrow transplantation in Thalassemia. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications, 1994:829-39.